rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Citius Oncology, Inc.

CTOR · Nasdaq

Health CareBiotechnologyNot moving yet

CTOR stood above a rising 150-day average in 2 of the last 52 weekly readings, and has been out of that trend for the last 50 weeks. It is 1.6% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

SEC filings

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 50
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
19 (+6)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 2 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1$0$1Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders19+6 on the quarter
New · exited7 · 1
Reported value$9.2M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
ARMISTICE CAPITAL, LLCreduced · filed 14 Aug 20268,705,589$5.7M-483,266−5.3%
BANK OF AMERICA CORPunchanged · filed 14 Aug 20263,835,160$2.5M00.0%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026546,325$355K+11,501+2.2%
UBS Group AGadded · filed 13 Aug 2026334,619$218K+297,779+808.3%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 2026245,407$160K-19,326−7.3%
VANGUARD FIDUCIARY TRUST COunchanged · filed 13 Aug 2026121,910$79K00.0%
IFP Advisors, Incunchanged · filed 20 Jul 2026107,424$70K00.0%
CITADEL ADVISORS LLCnew · filed 14 Aug 202690,586$59K+90,586
NORTHERN TRUST CORPunchanged · filed 13 Aug 202645,746$30K00.0%
STATE STREET CORPunchanged · filed 7 Aug 202642,900$28K00.0%
30 Sep 2024 – 30 Jun 2026
61319Sep 24Mar 25Sep 25Dec 25Jun 26

News

No headline names it lately.

Everyone who traded it

Carol Webb Company insiderDirector · last 19 Sep 20250 · 0
Dennis M. McGrath Company insiderDirector · last 19 Sep 20250 · 0
Eugene Myron Holuka Company insiderDirector · last 19 Sep 20250 · 0
Jaime Bartushak Company insiderChief Financial Officer · last 19 Sep 20250 · 0
Joel David Mayersohn Company insiderDirector · last 19 Sep 20250 · 0
Leonard L. Mazur Company insiderChief Executive Officer · last 19 Sep 20250 · 0
Myron Czuczman Company insiderChief Medical Officer · last 19 Sep 20250 · 0
Myron Z. Holubiak Company insiderSecretary · last 19 Sep 20250 · 0
Robert Joseph Smith Company insiderDirector · last 19 Sep 20250 · 0
Suren G. Dutia Company insiderDirector · last 19 Sep 20250 · 0

Same industry

MRNA ModernaLeading+147%
IOVA Iovance BiotherapeuticsLeading+126%
ABCL AbCellera BiologicsLeading+60%
HALO Halozyme TherapeuticsLeading+46%
XERS Xeris Biopharma HoldingsLeading+38%
ENTX Entera BioLeading+37%
HELP Helus PharmaLeading+36%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 30 Sep 2025-45.7%
Share count trendFY 2025 · to 23 Dec 20251.5%
Cash and equivalentsFY 2025 · to 30 Sep 2025$3.9M

Analyst forecasts

No analyst forecasts yet.